Last reviewed 2026-04-20 · How we verify

Best Available Treatment (best-available-treatment)

Not specified on Wikipedia

Best Available Treatment, manufactured by Pfizer, holds a prominent market position with 48 approved indications, making it one of the most versatile drugs available. Its competitive advantage lies in its broad range of indications, though specific clinical trial data is lacking, which may impact its adoption in certain markets. A key risk is the strong competition from alternative treatments such as Humira and Cosentyx, which offer similar therapeutic options for conditions like Psoriasis and Psoriatic Arthritis. The pipeline outlook remains robust, with the requirement for a PD-L1 companion diagnostic for several indications potentially enhancing its targeted use and efficacy.

At a glance

Mechanism of action

Unfortunately, the mechanism of action for best-available-treatment is not available on Wikipedia. This information is crucial for healthcare professionals to understand how the drug works and its potential interactions with other medications. Further research is needed to determine the exact mechanism of action for this drug.

Approved indications

• Acute Ischemic Stroke
• Acute Ischemic Stroke with a Large Vessel Occlusion
• Acute Ischemic Stroke with a Malignant Cerebral Edema
• Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema
• Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation
• Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater
• Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours
• Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device
• Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device
• Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device
• Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device
• Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device
• Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device
• Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours
• Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater
• Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation
• Acute Ischemic Stroke with a Large Vessel Occlusion
• Acute Ischemic Stroke with Malignant Cerebral Edema
• Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation
• Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater

Common side effects

• Blood sodium decreased
• Blood cholesterol increased
• Low density lipoprotein increased
• Blood bicarbonate decreased
• Blood phosphorus decreased
• Aspartate aminotransferase increased
• Blood alkaline phosphatase increased
• Blood bilirubin increased
• Neutrophil count decreased
• Blood glucose increased
• Alanine aminotransferase increased
• Cough

Drug interactions

• Aspirin
• Warfarin
• Ibuprofen
• Clopidogrel
• Pentoxifylline
• Dipyridamole
• Ticlopidine
• Alteplase
• Reteplase
• Tenecteplase
• Urokinase
• Streptokinase

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Best Available Treatment CI brief — competitive landscape report
• Best Available Treatment updates RSS · CI watch RSS
• Pfizer portfolio CI